Global CDMO Reach Catalent operates across 40 global sites and supports over 60 billion doses annually, highlighting a broad geographic and operational footprint to target multiple pharma, biotech, and consumer health customers with scalable development and manufacturing partnerships.

FDA Track Record With involvement in roughly half of all FDA approvals over the past decade and more than 1,000 active development programs, Catalent demonstrates strong regulatory experience and a robust pipeline partner for accelerated development timelines.

Innovation Pipeline Recent launches such as Qai for quality assurance and the development of helium-free gas chromatography show a commitment to advanced manufacturing technologies and process innovations that can reduce risk and increase efficiency for clients.

Strategic Partnerships Recent collaborations and asset divestitures, including a partnership expansion with Nanoscope Therapeutics and the sale of the Nottingham facility to Codis, indicate ongoing strategic moves to optimize capabilities and create co-development or end-to-end manufacturing opportunities.

Therapeutic Focus Active engagement in biologics and complex therapeutics, including antibodies and Zydis ODT patient-centric technologies, positions Catalent as a potential partner for companies seeking specialized formulations, delivery platforms, and multi-modality manufacturing expertise.